Singapore-based Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s CAR-T portfolio is highlighted by a proprietary allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein-Barr virus-specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform, TT11X, is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa’s pipeline also includes TT11, an autologous CD30.CAR-T therapy being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b).For more information on Tessa, visit www.tessacell.com.
Singapore-based Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s CAR-T portfolio is highlighted by a proprietary allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein-Barr virus-specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform, TT11X, is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa’s pipeline also includes TT11, an autologous CD30.CAR-T therapy being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b).For more information on Tessa, visit www.tessacell.com.
Singapore-based Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s CAR-T portfolio is highlighted by a proprietary allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein-Barr virus-specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform, TT11X, is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa’s pipeline also includes TT11, an autologous CD30.CAR-T therapy being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b).For more information on Tessa, visit www.tessacell.com.